Freeline Therapeutics Holdings plc Quarterly Nonoperating Income (Expense) in USD from Q1 2020 to Q1 2023

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Freeline Therapeutics Holdings plc quarterly/annual Nonoperating Income (Expense) history and growth rate from Q1 2020 to Q1 2023.
  • Freeline Therapeutics Holdings plc Nonoperating Income (Expense) for the quarter ending March 31, 2023 was $21.4M, a 1366% increase year-over-year.
  • Freeline Therapeutics Holdings plc annual Nonoperating Income (Expense) for 2022 was $9.84M, a 322% increase from 2021.
  • Freeline Therapeutics Holdings plc annual Nonoperating Income (Expense) for 2021 was $2.33M, a 62.8% decline from 2020.
  • Freeline Therapeutics Holdings plc annual Nonoperating Income (Expense) for 2020 was $6.26M, a 36.7% decline from 2019.
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2023 $21.4M +$20M +1366% Jan 1, 2023 Mar 31, 2023 6-K 2023-05-30
Q1 2022 $1.46M +$2.46M Jan 1, 2022 Mar 31, 2022 6-K 2023-05-30
Q1 2021 -$995K -$5.61M -122% Jan 1, 2021 Mar 31, 2021 6-K 2022-05-10
Q1 2020 $4.62M Jan 1, 2020 Mar 31, 2020 6-K 2021-05-17
* An asterisk sign (*) next to the value indicates that the value is likely invalid.